2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-145354
    FXIa-IN-7 2488952-56-1 98%
    FXIa-IN-7 is a selective and orally bioavailable factor XIa inhibitor with an IC50 value of 0.4 nM.
    FXIa-IN-7
  • HY-145610
    Mepixetil 98%
    Mepixetil is a potent antagonist of angiotensin II receptor.
    Mepixetil
  • HY-145611
    Mopivabil 2988562-84-9 99.66%
    Mopivabil is the antagonist of angiotensin II receptor.
    Mopivabil
  • HY-145841
    5-HT2A receptor agonist-2 528525-37-3 98%
    5-HT2A receptor agonist-2 is a highly potent serotonin 5-HT2 receptor agonists. 5-HT2A receptor agonist-2 inspires 5-HT2A, 5-HT2B, and 5-HT2C with EC50 values of 1.7, 0.58, and 0.50 nM, respectively.
    5-HT2A receptor agonist-2
  • HY-146173
    KCa1.1 channel activator-1 98%
    KCa1.1 channel activator-1 (compound 1E), a Quercetin hybrid derivative, is a selective vascular KCa1.1 channel channel stimulator. KCa1.1 channel activator-1 also displays CaV1.2 channel blocking activity. KCa1.1 channel activator-1 exhibits weak myorelaxant activity.
    KCa1.1 channel activator-1
  • HY-146174
    KCa1.1 channel activator-2 98%
    KCa1.1 channel activator-2 (compound 3F), a Quercetin hybrid derivative, is a selective vascular KCa1.1 channel stimulator. KCa1.1 channel activator-2 exhibits potent myorelaxant activity.
    KCa1.1 channel activator-2
  • HY-146205
    ATX inhibitor 18 2402772-30-7 98%
    ATX inhibitor 18 is a potent ATX inhibitor with an IC50 value of 24.2 nM. ATX inhibitor 18 shows antiproliferative activity and anti-fibrosis activity. ATX inhibitor 18 suppresses collagen deposition in TGF-β-mediated cardiac fibrosis.
    ATX inhibitor 18
  • HY-146305
    α-Glucosidase-IN-4 2410538-67-7 98%
    α-Glucosidase-IN-4 is a reversible and mixed type α-glucosidase inhibitor with an IC50 of 12.98 μM, a KI of 27.02 μM, and a KIS of 13.65 μM, respectively.
    α-Glucosidase-IN-4
  • HY-146332
    Collagen-IN-1 104260-73-3 98%
    Collagen-IN-1 (compound 3), an ortho-carbonyl hydroquinone derivative, is a selective inhibitor on collagen. Collagen-IN-1 inhibits agonist-induced platelet aggregation in a non-competitive manner with an IC50 value of 1.77 μM. Collagen-IN-1 reduces the expression of P-selectin, activation of glycoprotein IIb/IIIa, and release of adenosine triphosphate and CD63 from platelet. Collagen-IN-1 has the potential for platelet-related thrombosis diseases research.
    Collagen-IN-1
  • HY-146333
    TRAP-6-IN-1 2068737-10-8 98%
    TRAP-6-IN-1 (Compound 8) is a dual collagen and TRAP-6 inhibitor with IC50 values of 17.12 µM and 11.88 µM against collagen and TRAP-6, respectively. TRAP-6-IN-1 inhibits agonist-induced platelet aggregation in a non-competitive manner.
    TRAP-6-IN-1
  • HY-146420
    GRP78-IN-2 1882875-63-9 98%
    GRP78-IN-2 (Compound FL5) is a GRP78 (Glucose Regulated Protein 78 kDa) inhibitor. GRP78-IN-2 preferentially targeting cell surface GRP78 and shows potent antiangiogenic and anticancer activities without affecting other normal cells.
    GRP78-IN-2
  • HY-146441
    Prohibitin ligand 1 98%
    Prohibitin ligand 1 (Compound 22i), a cardioprotectant prohibitin ligand, induces a phosphorylation of the pro-survival factor STAT3. Prohibitin ligand 1 exhibits in vitro cardioprotectant activities at nanomolar concentrations.
    Prohibitin ligand 1
  • HY-146498
    Antiplatelet agent 1 2493297-12-2 98%
    Antiplatelet agent 1 (compound 7q) is a Ticagrelor analoguehas, possessing antiplatelet activity. Antiplatelet agent 1 can be used for researching platelet aggregation.
    Antiplatelet agent 1
  • HY-146499
    Antiplatelet agent 2 1395047-93-4 98%
    Antiplatelet agent 2 (compound 7p) is a Ticagrelor analoguehas, possessing antiplatelet activity. Antiplatelet agent 2 can be used for researching platelet aggregation.
    Antiplatelet agent 2
  • HY-14654B
    Aspirin DL-lysine 62952-06-1 98%
    Aspirin DL-lysine (ASA DL-lysine) is a lysine-containing aspirin derivative. Aspirin DL-lysine inhibits cyclooxygenase (COX) in platelets, blocks the synthesis of thromboxane A2 (TXA2), and thus inhibits platelet aggregation and activation. Aspirin DL-lysine can be used to study thrombin generation in patients with unstable angina pectoris.
    Aspirin DL-lysine
  • HY-14654C
    Aspirin calcium 69-46-5 98%
    Aspirin calcium is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin calcium induces apoptosis. Aspirin calcium inhibits the activation of NF-κB. Aspirin calcium also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis.
    Aspirin calcium
  • HY-14656R
    Diltiazem hydrochloride (Standard) 33286-22-5
    Diltiazem (hydrochloride) (Standard) is the analytical standard of Diltiazem (hydrochloride). This product is intended for research and analytical applications. Diltiazem hydrochloride is a Ca2+ influx inhibitor (slow channel blocker or calcium antagonist).
    Diltiazem hydrochloride (Standard)
  • HY-14664B
    (3R,5S)-Fluvastatin 155229-75-7 98%
    (3R,5S)-Fluvastatin is the 3R,5S-isomer Fluvastatin. Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.
    (3R,5S)-Fluvastatin
  • HY-146650
    LpxC-IN-9 2756125-46-7 98%
    LpxC-IN-9 (compound 19) is a potent LpxC inhibitor. LpxC-IN-9 has antibacterial and hypotensive effects. LpxC-IN-9 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    LpxC-IN-9
  • HY-146651
    MPO-IN-4 2088545-68-8 98%
    MPO-IN-4 (compound 12) is a potent and selective myeloperoxidase (MPO) inhibitor with an IC500 of 25 nM. MPO-IN-4 has no effect on methyl guanine methyl transferase (MGMT).
    MPO-IN-4
Cat. No. Product Name / Synonyms Application Reactivity